Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo hóa học:" Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients | Journal of Translational Medicine BioMed Central Open Access Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2 Melan-A-specific T-cell clonotypes of melanoma patients Federico Serana1 Alessandra Sottini1 Luigi Caimi1 Belinda Palermo2 Pier Giorgio Natali2 Paola Nisticò2 and Luisa Imberti 1 Address diagnostics Department Spedali Civili di Brescia 25123 Brescia Italy and 2Immunology Laboratory Regina Elena Cancer Institute via delle Messi d Oro 156 00158 Rome Italy Email Federico Serana - federico.serana@gmail.com Alessandra Sottini - asottini@libero.it Luigi Caimi - caimi@med.unibs.it Belinda Palermo - belinda.p@fastwebnet.it Pier Giorgio Natali - natalipg2002@yahoo.it Paola Nisticò - nistico@ifo.it Luisa Imberti - limberti@yahoo.it Corresponding author Published 24 March 2009 Received 3 March 2009 _ -T_J.IA I IO ÍI A-ra cmi 1 TI Accepted 24 March 2009 Journal of Translational Medicine 2009 7 21 doi 10.1186 1479-5876-7-21 This article is available from http www.translational-medicine.cOm content 7 1 21 2009 Serana et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Assessment of T-cell diversity besides giving insights about the molecular basis of tumor antigen recognition has clinical implications since it provides criteria for evaluating antigenspecific T cells clinically relevant for spontaneous and vaccine-induced anti-tumor activity. Melan-A is one of the melanoma antigens most frequently recognized by peripheral and tumor-infiltrating lymphocytes in HLA-A2 melanoma patients. Many clinical trials involving anti-tumor vaccination have been conducted using modified versions of this peptide. Methods We conducted an in-depth .